Trial Profile

A Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VAY736 in Rheumatoid Arthritis Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ianalumab (Primary) ; Ianalumab (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Pharmacokinetics
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

08 Feb 2018 Status changed from active, no longer recruiting to completed.
29 Nov 2016 Planned End Date changed from 1 Mar 2018 to 1 Dec 2017.
29 Nov 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com